Promega Executive and Leadership Team

William Linton, the Chairman, Chief Executive Officer & President at Promega, directs the overarching corporate strategy and long-term vision for the biotechnology manufacturer. Overseeing the development of enzymes and molecular biology products, Linton ensures alignment between research initiatives and global market demands. This leadership role involves constant engagement with the Board to maintain the company's commitment to scientific advancement. By fostering a culture of innovation, William Linton drives the organization toward sustainable growth in genomics and cellular analysis. The Chairman, Chief Executive Officer & President manages high-level partnerships that expand the reach of Promega across international markets. Through rigorous oversight of product portfolios, Linton secures the company's position as a leader in drug discovery and genetic identity. Ultimately, the executive maintains the operational integrity required to support complex molecular biology workflows while navigating the evolving landscape of the global life sciences industry.

Chris Yarbro, the Chief Financial Officer at Promega, manages the fiscal health and capital allocation strategies for the biotechnology firm. Overseeing financial planning and analysis, Yarbro ensures the company maintains the resources required to sustain research in genomics and cellular analysis. This leadership role involves coordinating with the Board to optimize investment in drug discovery infrastructure. By implementing rigorous financial controls, Chris Yarbro drives profitability and supports the company's mission of providing high-quality molecular biology products. The Chief Financial Officer monitors global market trends to mitigate risks associated with international operations and supply chain fluctuations. Through strategic budgeting, Yarbro enables the scaling of manufacturing capabilities to meet rising demand for protein expression tools. Ultimately, the Chief Financial Officer secures the financial stability necessary for the company to continue delivering innovative solutions to the life sciences sector while maintaining a strong balance sheet for future growth.

Kristen Yetter, the General Manager and President at Promega, executes the operational strategy for the company's core manufacturing and service divisions. Overseeing the production of enzymes and molecular biology reagents, Yetter ensures that quality standards remain consistent across all product lines. This leadership role involves managing cross-functional teams to streamline workflows in genomics and cellular analysis. By optimizing manufacturing processes, Kristen Yetter drives operational excellence and supports the company's commitment to scientific precision. The General Manager and President coordinates with other executive leaders to align production capacity with global demand for drug discovery tools. Through the implementation of lean manufacturing principles, Yetter enhances efficiency and reduces lead times for critical research supplies. Ultimately, the General Manager and President maintains the operational rigor necessary for the company to deliver reliable, high-performance products to the global scientific community while fostering a culture of continuous improvement.

Brian Schiro, the Chief Information Officer at Promega, architects the digital infrastructure supporting the company's complex biotechnology manufacturing operations. Overseeing the integration of data systems across genomics and protein analysis divisions, Schiro ensures seamless information flow for global research teams. This leadership role involves implementing advanced cybersecurity protocols to protect proprietary drug discovery data. By modernizing enterprise resource planning, Brian Schiro drives operational efficiency and data-driven decision-making throughout the organization. The Chief Information Officer collaborates with other C-suite leaders to align technological capabilities with the company's long-term growth objectives. Through the deployment of scalable cloud solutions, Schiro supports the rapid expansion of molecular biology product lines. Ultimately, the Chief Information Officer maintains the robust digital backbone necessary for the company to deliver high-quality reagents and analytical tools to the scientific community while ensuring compliance with international data standards.

Kara Machleidt, the Global Chief Revenue Officer, Strategic Business Lead at Promega, directs the commercial strategy and revenue growth initiatives across all biotechnology product lines. Overseeing international sales teams, Machleidt ensures the effective distribution of genomics and protein analysis tools to global research institutions. This leadership role involves identifying emerging market opportunities in drug discovery and genetic identity. By aligning sales operations with customer needs, Kara Machleidt drives market penetration and strengthens the company's competitive position. The Global Chief Revenue Officer, Strategic Business Lead collaborates with product development teams to translate scientific innovation into commercial success. Through the execution of regional expansion strategies, Machleidt scales the company's footprint in key life sciences hubs. Ultimately, the Global Chief Revenue Officer, Strategic Business Lead maintains a focus on customer-centric growth, ensuring that the company's molecular biology solutions reach researchers efficiently while maximizing long-term revenue potential.